{
    "organizations": [],
    "uuid": "d04e5c027cdbb52fefb9cb01aea049d5dd0a8919",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mesoblast-says-primary-endpoint-ac/brief-mesoblast-says-primary-endpoint-achieved-in-a-phase-3-cell-therapy-trial-idUSFWN1QB0ZR",
    "ord_in_thread": 0,
    "title": "BRIEF-Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Mesoblast Ltd:\n* ‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST‘S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-22T08:16:00.000+02:00",
    "crawled": "2018-02-22T17:49:27.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "mesoblast",
        "ltd",
        "endpoint",
        "successfully",
        "achieved",
        "mesoblast",
        "phase",
        "cell",
        "therapy",
        "trial",
        "acute",
        "graft",
        "versus",
        "host",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}